Systemic Sclerosis Clinical Trial
Official title:
A Phase 2, Single-center, Randomised, Double-blind, Placebo-controlled, Cross-over Cold Challenge Study Investigating the Effect of C21 on Cold-induced Vasoconstriction in Subjects With Raynaud's Phenomenon (RP) Secondary to Systemic Sclerosis (SSc)
Verified date | July 2022 |
Source | Vicore Pharma AB |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a randomised, double-blind, placebo-controlled, cross-over phase 2 trial investigating the effect of C21 on cold-induced vasoconstriction in subjects with Raynaud's phenomenon secondary to systemic sclerosis. The purpose of the trial is to achieve a vasodilatory effect in subjects with Raynaud's phenomenon by stimulation of the AT2R (angiotensin II type 2 receptor) with C21.
Status | Completed |
Enrollment | 20 |
Est. completion date | December 14, 2020 |
Est. primary completion date | December 14, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 19 Years to 75 Years |
Eligibility | Inclusion Criteria: 1. Written informed consent must be obtained before any trial related procedures are performed. 2. Subjects diagnosed with SSc according to European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) criteria 3. Age 19-75 years inclusive 4. RP secondary to SSc as determined by the investigator, and with a typical frequency of attacks during the winter months (November-March) of on average at least 5 per week. Exclusion Criteria: 1. Smoking (including E-cigarettes) or use of nicotine replacement therapy for three months prior to Visit 1 and during the trial. 2. BMI >30 3. Mixed connective tissue disease or "overlap" (i.e. those who satisfy more than one set of ACR criteria for a rheumatic disease). 4. Concurrent serious medical condition with special attention to cardiac or ophthalmic conditions which in the opinion of the investigator makes the patient inappropriate for this study 5. Malignancy within the past 5 years with the exception of in situ removal of basal cell carcinoma and cervical intraepithelial neoplasia grade I 6. Planned major surgery within the duration of the study 7. Subjects who forsake any alcohol intake or have known uncontrolled allergic conditions or allergy/hypersensitivity to any components of the trial drug or placebo excipients (see Section 7.1) 8. Blood donation (or corresponding blood loss) within three months prior to Visit 1 9. Treatment with any of the medications listed below within 4 weeks prior to Visit 1: - Any dose-change or initiation of vasoactive substances , and not able or willing to withhold these medications for 3 days preceding Visit 2 and Visit 3, respectively - Iloprost - Any treatment with CYP3A4 inducers (e.g. rifampicin, phenytoin, St John's Wort) - Any treatment with CYP3A4 inhibitors (e.g. clarithromycin, ketoconazole, nefazodone, itraconazole, ritonavir) - Any treatment with medicines that are substrates of CYP1A2, CYP3A4 or CYP2C9 with a narrow therapeutic range - Any experimental drug - Any systemic immunosuppressive therapy other than: - Inhaled corticosteroids which can be used throughout the trial period - The continuation of stable doses of <10 mg prednisolone - Mycophenolate mofetil (MMF) which must be withheld for 3 days preceding Visit 2 and Visit 3 10. Any of the following findings at the time of screening: - Finger temperature below 27°C after acclimatising at an ambient temperature of 23°C for a period of 20 minutes - Prolonged QTcF (>450 ms), cardiac arrhythmias or any clinically significant abnormalities in the resting ECG, as judged by the Investigator - Positive results for HBsAg, HCVAb or HIV 1+2 Ag/Ab - Positive serum pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) - Clinically significant abnormal laboratory value at Visit 1 indicating a potential risk for the subject if enrolled in the trial as evaluated by the Investigator 11. Pregnant or breast-feeding female subjects. 12. Female subjects of childbearing potential not willing to use contraceptive methods described in Section 5.3.1. 13. Male subjects not willing to use contraceptive methods described in Section 5.3.1. 14. Participation in any other interventional trial during the trial period 15. Subjects known or suspected of not being able to comply with this trial protocol (e.g. due to alcoholism, drug dependency or psychological disorder) |
Country | Name | City | State |
---|---|---|---|
United Kingdom | Department of Rheumatology, Salford Royal Hospital | Manchester | Salford |
Lead Sponsor | Collaborator |
---|---|
Vicore Pharma AB | SGS Life Sciences, a division of SGS Belgium NV |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Change in Finger Temperature From Intake of IMP to Start of Cold Challenge | From intake of IMP to start of cold challenge (0-40 min) | ||
Other | Nailfold Capillaroscopy (Including Red Blood Cell Velocity Measurements) | Nailfold capillaroscopy mean velocity was measured as red blood cell velocity before cold challenge and post recovery | Before cold challenge (at 40 min) and post-recovery (at 55 min) | |
Primary | Area Under the Curve for Rewarming of Each Finger After Cold Challenge (AUC) as Measured by Thermography | Area under the curve for rewarming of each finger after cold challenge as measured by thermography for 15 min | For 15 min after cold challenge (40-55 min after IMP [investigational manufacturing product] administration) | |
Secondary | Maximum Skin Temperature After Rewarming (MAX) | Maximum skin temperature after rewarming within 15 min after cold challenge | For 15 min after cold challenge (40-55 min after IMP administration) | |
Secondary | The Distal Dorsal Difference, Defined as the Difference in Temperature Between the Dorsum and the Finger (DDD) | The distal dorsal difference, defined as the difference in temperature between the dorsum and the finger (DDD), from administration of IMP until before cold challenge (0 to 40 min) | Baseline, 10, 20, 30 and 40 min | |
Secondary | Gradient of Rewarming in the First 2 Minutes Post-cold Challenge (GRAD) | 2 min after cold challenge (40-42 min after IMP administration) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03274076 -
Evaluation of Tofacitinib in Early Diffuse Cutaneous Systemic Sclerosis (dcSSc)
|
Phase 1/Phase 2 | |
Completed |
NCT04300426 -
Safety and Efficacy of Anaerobic Cultivated Human Intestinal Microbiome Transplantation in Systemic Sclerosis (ReSScue)
|
Phase 2 | |
Recruiting |
NCT06058091 -
RY_SW01 Cell Injection Therapy in Systemic Sclerosis
|
Phase 1/Phase 2 | |
Recruiting |
NCT04356755 -
Subcutaneous Injections of ASC to Heal Digital Ulcers in Patients With Scleroderma.
|
Phase 2 | |
Suspended |
NCT06210945 -
Study to Evaluate the Safety, Tolerability, and Activity of CM-101 in Patients With Systemic Sclerosis
|
Phase 2 | |
Not yet recruiting |
NCT05947682 -
Manufacturing of Allogeneic Adipose Tissue-derived Mesenchymal Stromal Cells for Treatment of Severe Systemic Sclerosis
|
N/A | |
Not yet recruiting |
NCT04303208 -
Sirtuin 3 and Sirtuin 7 in Systemic Sclerosis
|
N/A | |
Not yet recruiting |
NCT05177380 -
Efficacy of a Personalized Rehabilitation Program of Facial Involvement in Systemic Sclerosis
|
N/A | |
Recruiting |
NCT02551042 -
CSL Behring Sclero XIII
|
Phase 2 | |
Terminated |
NCT02243111 -
Detecting Pulmonary Arterial Hypertension (PAH) in Patients With Systemic Sclerosis (SSc) by Ultrasound
|
N/A | |
Terminated |
NCT02246348 -
Evaluating Lung Doppler Signals in Patients With Systemic Sclerosis (SSc)
|
N/A | |
Completed |
NCT01933334 -
Safety and Tolerability of Pirfenidone in Patients With Systemic Sclerosis−Related Interstitial Lung Disease (SSc-ILD) (LOTUSS)
|
Phase 2 | |
Completed |
NCT01468792 -
Hemodynamic Changes in Connective Tissue Disease
|
N/A | |
Terminated |
NCT00848107 -
Open-Label Study of Oral Treprostinil in Digital Ulcers
|
Phase 2 | |
Completed |
NCT00984932 -
Effect of Rosuvastatin on Systemic Sclerosis-related Pulmonary Hypertension
|
Phase 3 | |
Completed |
NCT00074568 -
Scleroderma Registry
|
||
Not yet recruiting |
NCT06412614 -
Evaluation of Patients With Systemic Sclerosis Without Specific or Associated Autoantibodies
|
||
Terminated |
NCT00622687 -
Effect of Different Iloprost Doses on Symptoms in Systemic Sclerosis
|
Phase 2 | |
Recruiting |
NCT04464434 -
Upfront Autologous HSCT Versus Immunosuppression in Early Diffuse Cutaneous Systemic Sclerosis
|
Phase 4 | |
Recruiting |
NCT04246528 -
SPIN Self-Management Feasibility Trial With Progression to Full-scale Trial (SPIN-SELF)
|
N/A |